Canadian multicenter azidothymidine trial: AZT pharmacokinetics

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Azidothymidine (AZT) is a key antiretroviral medication used in managing Human Immunodeficiency Virus (HIV) infection.
• Understanding the pharmacokinetics of AZT is crucial for optimizing treatment regimens and patient outcomes.
• Previous pharmacokinetic data for AZT primarily focused on individuals with advanced HIV disease.

Purpose of the Study:

• To characterize the pharmacokinetic profile of azidothymidine (AZT) in a substantial cohort of early-stage, asymptomatic HIV-infected individuals.
• To compare the pharmacokinetic parameters of AZT in early HIV disease with existing data from patients with more advanced stages of the infection.

Main Methods:

• A multicenter, prospective, descriptive pharmacokinetic study involving 66 HIV-infected males.
• Participants received a single 400-mg oral dose of AZT under fasting conditions.
• Pharmacokinetic measurements for AZT and its metabolite glucuronylazidothymidine (GAZT) were conducted over an 8-hour period.

Main Results:

• Pharmacokinetic parameters for AZT in patients with normal hepatic function included an AUC of 9.9 +/- 5.7 microM.h and Cmax of 7.3 +/- 4.7 microM.
• Parameters for GAZT included an AUC of 35.7 +/- 10.3 microM.h and Cmax of 21.3 +/- 7.3 microM.
• No significant pharmacokinetic differences were observed based on study site, disease classification, smoking status, or presence of hepatic dysfunction, though a trend towards higher AZT AUC and earlier Cmax was noted in hepatic dysfunction cases.

Conclusions:

• The pharmacokinetics of azidothymidine (AZT) in early, asymptomatic HIV infection are comparable to those reported in patients with later-stage HIV disease.
• These findings suggest that standard AZT dosing may be appropriate for individuals in the early stages of HIV infection.
• Further research could explore potential minor variations in specific patient subgroups.